TAMPA, Fla. – Moffitt Cancer Center is opening a study that will determine if a new tumor test known as Decipher® can find aggressive prostate cancer in black men, as well as in men of other ethnicities.
The Moffitt study, referenced as the VanDAAM Study: Validation of Decipher Test in African American Men with Prostate Cancer, will collect the Decipher samples donated from African American men to test how aggressive their disease may be.
Kosj Yamoah, MD, PhD, assistant member of the Radiation Oncology Department and Cancer Epidemiology Program, is leading the study.
Dr. Yamoah's research remains focused on addressing prostate cancer disparities in African Americans. His recent results show that some African American men with prostate cancer may have a better chance of survival if they are treated with a different approach than the standard of care. He also plans to refine the set of biomarkers that will capture these differences in order to develop decision-making and treatment approaches to help reduce the disparities in outcomes for African Americans.
"African American men have historically experienced a higher incidence of mortality from prostate cancer than men of other races and ethnicities, and clinicians have long sought a better understanding of what drives this more aggressive disease," said Yamoah. "The ability to identify a subset of African American men who harbor aggressive disease will enable clinicians to more accurately identify appropriate treatments to enhance disease control and ultimately help to improve outcomes in this patient population."
Participants do not need to come to Moffitt to take part in this study; they can work with their community physicians.
For more information, contact study coordinator Angelina Fink at 813-745-2588 or Angelina.Fink@Moffitt.org.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. One of the three largest cancer centers in the United States based on patient volume, the Tampa-based facility is one of only 45 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in Florida and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. Moffitt devotes more than 2 million square feet to research and patient care. With more than 5,000 team members, Moffitt has an economic impact in the state of $1.9 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.